OXTELLAR XR Drug Patent Profile
✉ Email this page to a colleague
When do Oxtellar Xr patents expire, and what generic alternatives are available?
Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are eleven patents protecting this drug and two Paragraph IV challenges.
This drug has fourteen patent family members in ten countries.
The generic ingredient in OXTELLAR XR is oxcarbazepine. There are twenty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxtellar Xr
A generic version of OXTELLAR XR was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXTELLAR XR?
- What are the global sales for OXTELLAR XR?
- What is Average Wholesale Price for OXTELLAR XR?
Summary for OXTELLAR XR
| International Patents: | 14 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 131 |
| Clinical Trials: | 3 |
| Patent Applications: | 5,298 |
| Drug Prices: | Drug price information for OXTELLAR XR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OXTELLAR XR |
| What excipients (inactive ingredients) are in OXTELLAR XR? | OXTELLAR XR excipients list |
| DailyMed Link: | OXTELLAR XR at DailyMed |
Recent Clinical Trials for OXTELLAR XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Colorado, Denver | Phase 4 |
| Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen Hospital | Phase 4 |
| Collaborative Care Initiative, LLC | Phase 4 |
Pharmacology for OXTELLAR XR
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Paragraph IV (Patent) Challenges for OXTELLAR XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| OXTELLAR XR | Extended-release Tablets | oxcarbazepine | 150 mg and 300 mg | 202810 | 1 | 2013-04-12 |
| OXTELLAR XR | Extended-release Tablets | oxcarbazepine | 600 mg | 202810 | 1 | 2013-03-20 |
US Patents and Regulatory Information for OXTELLAR XR
OXTELLAR XR is protected by eleven US patents.
Patents protecting OXTELLAR XR
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modified-release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Method of treating seizures using modified release formulations of oxcarbazepine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OXTELLAR XR
See the table below for patents covering OXTELLAR XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2026815 | PRÉPARATIONS À LIBÉRATION CONTRÔLÉE D'OXCARBAZÉPINE AYANT UN PROFIL DE LIBÉRATION SIGMOÏDE (CONTROLLED RELEASED PREPARATIONS OF OXCARBAZEPINE HAVING SIGMOIDAL RELEASE PROFILE) | ⤷ Sign Up |
| China | 101489560 | Controlled released preparations of oxcarbazepine having sigmoidal release profile | ⤷ Sign Up |
| Germany | 602007012236 | ⤷ Sign Up | |
| Australia | 2007242984 | Controlled released preparations of oxcarbazepine having sigmoidal release profile | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
